Malaria drug hydroxychloroquine fails to prevent COVID-19 in high-profile study

Malaria drug hydroxychloroquine fails to prevent COVID-19 in high-profile study

Hydroxychloroquine
FILE PHOTO: The drug hydroxychloroquine, pushed by US President Donald Trump and others in recent months as a possible treatment to people infected with the coronavirus, is displayed at the Rock Canyon Pharmacy in Provo, Utah. (REUTERS/George Frey)

WASHINGTON: The malaria drug promoted by US President Donald Trump as a treatment for COVID-19 was ineffective in preventing infection in people exposed to the coronavirus, according to a widely anticipated clinical trial released on Wednesday (Jun 3).

The new trial found no serious side effects or heart problems from the use of hydroxychloroquine.

Vocal support from Trump kicked off a heated debate and raised expectations for the decades-old drug that could be a cheap and widely available tool in fighting the pandemic that has infected 6.4 million people and killed more than 382,000 worldwide

In the first major study comparing hydroxychloroquine to a placebo to gauge its effect against the new coronavirus, researchers tested 821 people who had recently been exposed to the virus or lived in a high-risk household.

The study was led by a team at the University of Minnesota, and their paper was published in the New England Journal of Medicine.

READ: WHO to resume hydroxychloroquine coronavirus trials

The majority of them - 719 - were deemed to have had "high-risk" exposure because they wore neither a face mask nor an eye shield at the time, while the rest were "moderate-risk" because they covered their face but did not have goggles.

All participants were randomly assigned to receive either hydroxychloroquine - which is certified for use against malaria, rheumatoid arthritis and lupus - or a placebo, within four days.

The study found 11.8 per cent of subjects given hydroxychloroquine developed symptoms compatible with COVID-19, compared with 14.3 per cent who got a placebo. That difference was not statistically significant, meaning the drug was no better than placebo.

"Our data is pretty clear that for post-exposure, this does not really work," said Dr David Boulware, the trial's lead researcher and an infectious disease physician at the University of Minnesota.

Several trials of the drug have been stopped over concerns about its safety for treating COVID-19 that were raised by health regulators and previous less rigorous studies.

READ: France, Italy, Belgium act to stop use of hydroxychloroquine for COVID-19 on safety fears

"I think both sides - one side who is saying 'this is a dangerous drug' and the other side that says 'this works' - neither is correct," said Boulware.

In March, Trump said hydroxychloroquine used in combination with the antibiotic azithromycin had "a real chance to be one of the biggest game-changers in the history of medicine" with little evidence to back up that claim. 

He later said he took the drugs preventively after two people who worked at the White House were diagnosed with COVID-19, the illness caused by the novel coronavirus.

Hydroxychloroquine - which has anti-inflammatory and antiviral properties - inhibited the virus in laboratory experiments. But these type of human trials are needed to definitively demonstrate whether the drug's benefits, if any, outweigh the risks when compared with a placebo.

Proponents of the drug as a COVID-19 treatment argue it may need to be administered at an earlier stage in the disease to be effective. Others have suggested that it needs to be used in combination with the mineral zinc, which can help boost the immune system.

More than 20 per cent of the trial subjects also took zinc, which had no significant effect.

The US Food and Drug Administration cautioned in late April against the use of hydroxychloroquine in patients with heart disease due to an increased risk of dangerous cardiac rhythm problems.

Boulware said his trial had fewer participants than initially planned because of difficulty enrolling new subjects after the FDA's warning.

On Tuesday, the British medical journal the Lancet said it had concerns about data behind an influential article that found hydroxychloroquine increased the risk of death in COVID-19 patients, a conclusion that undercut scientific interest in the medicine.

Boulware was one of the signatories of an open letter from doctors that called attention to potential problems with that study.

Some European governments banned hydroxychloroquine for COVID-19 patients, and US hospitals have significantly cut back on its use.

In the University of Minnesota trial, 40 per cent of those who took hydroxychloroquine reported less serious side effects like nausea and abdominal discomfort versus 17 per cent in the placebo group.

Results of another University of Minnesota placebo-controlled trial testing hydroxychloroquine as a coronavirus treatment rather than to prevent infection is expected soon.

READ: Hydroxychloroquine combination risky for cancer patients with COVID-19, says study

Martin Landray, a professor of medicine and epidemiology at the University of Oxford, said more research was needed to know for sure whether hydroxychloroquine might have a moderately positive effect.

"The study is too small to be definitive," said Landray, who was not involved in the trial.

The results "makes it very unlikely that there is a large effect (e.g. a halving in the risk of infection) but cannot rule out a more modest difference (eg a reduction of one-quarter or one-third) which would still be very valuable," he added.

BOOKMARK THIS: Our comprehensive coverage of the coronavirus outbreak and its developments

Download our app or subscribe to our Telegram channel for the latest updates on the coronavirus outbreak: https://cna.asia/telegram

Source: Agencies

Bookmark